Asthma remodeling: Ics, new therapies, personalized care.

Emma Johansson*

Department of Respiratory Medicine, Lund University, Sweden

Introduction

Airway remodeling is a central feature of asthma, contributing significantly to disease severity and therapeutic resistance. This review highlights the cellular and molecular mechanisms driving these structural changes, including inflammation, smooth muscle hypertrophy, and extracellular matrix deposition. Understanding these processes is key to developing novel therapeutic strategies that move beyond symptom control to modify the disease course [1].

Inhaled corticosteroids (ICS) have been the cornerstone of asthma management for decades, demonstrating remarkable efficacy in controlling inflammation and preventing exacerbations. This article provides a historical perspective on ICS, discusses their evolving role in modern asthma and COPD treatment, and explores future directions, including precision medicine approaches and novel delivery systems to optimize their benefits [2].

This review delves into the complex processes of airway remodeling in asthma, from cellular and molecular mechanisms to potential therapeutic interventions. It highlights how persistent inflammation, fibroblast activation, and extracellular matrix deposition contribute to irreversible structural changes. The article explores emerging strategies aimed at reversing or attenuating remodeling, offering new avenues for improving patient outcomes [3].

The GINA 2023 report introduces significant updates to asthma management guidelines, particularly emphasizing individualized therapy and the early use of combination inhaled corticosteroid-formoterol as a reliever. This summary outlines the key changes, aiming to improve asthma control, reduce exacerbations, and minimize overtreatment or undertreatment by aligning therapy with individual patient needs and disease severity [4].

Epithelial-mesenchymal transition (EMT) is increasingly recognized as a crucial player in the pathogenesis of airway remodeling in asthma. This article explores how airway epithelial cells, under chronic inflammatory stress, can transform into mesenchymal-like cells, contributing to fibrosis, smooth muscle hyperplasia, and altered airway mechanics. Targeting EMT pathways represents a promising therapeutic avenue to halt or reverse structural changes [5].

This systematic review and meta-analysis provides a comprehensive evaluation of the clinical efficacy and safety profiles of inhaled corticosteroids in asthma patients. The findings reaffirm the indispensable role of ICS in improving lung function, reducing asthma exacerbations, and enhancing quality of life, while also critically assessing their potential systemic and local side effects to guide optimal prescribing practices [6].

Airway remodeling in asthma is a complex process involving structural changes in the bronchial wall, driven by chronic inflammation and repair mechanisms. This article elucidates the pathophysiology of these changes and explores current and emerging therapeutic strategies. It discusses how targeting specific signaling pathways and cellular interactions could offer new ways to prevent or reverse remodeling, complementing existing ICS therapies [7].

This review summarizes current guidelines for managing adult asthma, focusing on the essential role of inhaled corticosteroids, often in combination with long-acting beta-agonists. It also discusses the integration of new therapeutic options, particularly biologic agents for severe asthma phenotypes, highlighting a paradigm shift towards personalized medicine to achieve better disease control and improve patient quality of life [8].

This systematic review investigates the impact of inhaled corticosteroids on the intricate process of airway remodeling in asthma. It synthesizes evidence regarding the ability of ICS to mitigate structural changes, such as fibrosis and smooth muscle hypertrophy, and to influence the cellular components involved in remodeling. The review assesses the limitations and strengths of current research and points to future research directions [9].

The current landscape of asthma management relies heavily on inhaled corticosteroids for inflammation control, yet newer approaches are continually emerging. This article explores the evolving strategies, including the increasing role of biologics for severe asthma and personalized treatment algorithms. It critically evaluates the efficacy and safety of these advancements, offering insights into future directions for optimizing patient care [10].

***Correspondence to:** Emma Johansson, Department of Respiratory Medicine, Lund University, Sweden. E-mail: emma.johansson@lu.se

Received: 01-May-2025, Manuscript No. AAJPCR-25-204; **Editor assigned:** 05-May-2025, Pre QC No. AAJPCR-25-204 *(PQ)*; **Reviewed:** 23-May-2025, QC No. AAJPCR-25-204; **Revised:** 03-Jun-2025, Manuscript No. AAJPCR-25-204 *(R)*; **Published:** 12-Jun-2025, DOI: 10.35841/aajpcr-8.3.204

Citation: Johansson E. Asthma remodeling: Ics, new therapies, personalized care. J Pulmonol Clin Res. 2025;08(03):204.

Conclusion

Airway remodeling, a central feature of asthma, significantly contributes to disease severity and therapeutic resistance through processes like inflammation, smooth muscle hypertrophy, and extracellular matrix deposition. Understanding the cellular and molecular mechanisms driving these structural changes, including the role of Epithelial-Mesenchymal Transition in fibrosis and smooth muscle hyperplasia, is crucial for developing novel therapeutic strategies aimed at modifying the disease course rather than merely controlling symptoms. Inhaled corticosteroids (ICS) have been the cornerstone of asthma management for decades, demonstrating remarkable efficacy in controlling inflammation and preventing exacerbations. Their role is continuously evolving, with discussions on precision medicine approaches and novel delivery systems to optimize benefits.

Current guidelines, such as the GINA 2023 report, introduce significant updates emphasizing individualized therapy and the early use of combination ICS-formoterol as a reliever, aiming to improve control and reduce exacerbations. Beyond traditional ICS, new therapeutic options, including biologic agents for severe asthma phenotypes, are integrated into management strategies, highlighting a paradigm shift towards personalized medicine to enhance patient quality of life. Systematic reviews continue to reaffirm the indispensable role of ICS in improving lung function and critically assess their impact on mitigating airway remodeling, guiding optimal prescribing practices while also exploring future research directions in this complex process. The ongoing exploration of pathophysiology and targeted interventions represents a dynamic effort to prevent or reverse structural changes in asthma.

References

1. Zhiheng X, Yuan W, Zhenling L. Airway remodeling in asthma: *Current knowledge and future trends. Clin Transl Allergy.* 2022;12:e12165.
2. Sally W, Anne D, Paul O. Inhaled Corticosteroids: *A Century of Use and the Future of Asthma and COPD Management. Am J Respir Crit Care Med.* 2023;208:22-30.
3. Jie D, Haixia Y, Peng X. Targeting airway remodelling in asthma: from mechanism to therapeutic opportunities. *Signal Transduct Target Ther.* 2021;6:213.
4. Helen R, David P, *Guy B. GINA* 2023: What's New? Eur Respir J. 2023;62:2301358.
5. Yichen L, Juanjuan W, Jinshuang S. The Role of Epithelial-Mesenchymal *Transition in Airway Remodeling in Asthma. Front Pharmacol.* 2021;12:785087.
6. Xiaoli W, Ruijin J, Juan L. Clinical efficacy and safety of inhaled corticosteroids in asthma: A systematic review and meta-analysis. *Respir Med.* 2022;204:106969.
7. Jing-Chun L, Peng X, Ling-Yao *Z. Pathophysiology and therapeutic strategy of airway remodeling in asthma. World J Clin Cases.* 2022;10:4372-4384.
8. Monica K, Sebastian J, Thomas C. Asthma in adults: *A review of current guidelines and new therapeutic options. J Allergy Clin Immunol.* 2023;152:301-314.
9. Emily W, Joelle W, Helen R. Impact of Inhaled Corticosteroids on Airway Remodeling in Asthma: *A Systematic Review. Respiration.* 2024;epub:1-13.
10. E. L. A. Brusselle, G. G. Brusselle, M. J. Adcock. Asthma management: *Current landscape and future perspectives. Respir Med.* 2023;215:107297.

Citation: *Johansson E. Asthma remodeling: Ics, new therapies, personalized care. J Pulmonol Clin Res. 2025;08(03):204.*